Intestinal Microbiota Associated With The Efficacy Of Immune Checkpoint Inhibitor Therapy With Anti-Pd-1/ Pd-L1 Antibody
Author(s): Tadashi Ohara, Yasuyuki Taki
We explained about reports of fecal bacteria that could be biomarkers related to the efficacy of immune checkpoint inhibitor therapy with
anti-PD-1/PD-L1 antibody against melanoma, non-small cell lung carcinoma (NSCLC), urothelial and renal cell carcinoma (UTC/RCC).
It has been reported that the proportion of bacteria in the family Ruminococcaseae and Faecalibacterium affects the efficacy of immune
checkpoint inhibitor therapy as biomarkers against melanoma, and Akkermansia muchiniphila as a biomarker against NSCLC and UTC/
RCC. However, it is unlikely that these intestinal bacteria can be applied to all carcinomas, and the mechanism of antitumor effects in these
bacteria has not yet been fully elucidated.
Will be updated soon